Jorge de Jesus Miranda, MD
Endocrinology, Diabetes & Metabolism · San Juan, PRNPI 1376630202
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (54.7%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. 21 manufacturers reported payments, led by Johnson & Johnson at 45.1% of the total. Reporting peaked in 2019 at $17,421 and has fallen 93.0% since, to $1,227 in 2025. Among endocrinology, diabetes & metabolism clinicians in PR with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 275 payments — averaging $109.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$14K
- Sanofi-aventis U.S. LLC$6K
- AbbVie$4K
- AstraZeneca$1K
- Novo Nordisk$1K
- Boehringer Ingelheim$764
- plus $3K from 15 others
What the payments were for
- Consulting fees$4,07514%
- Speaking & faculty fees$16,41655%
- Food & beverage$9,35731%
- Education$1400%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 32 | $13,537 |
| Sanofi-aventis U.S. LLC | 26 | $5,711 |
| AbbVie | 11 | $4,016 |
| AstraZeneca | 49 | $1,385 |
| Novo Nordisk | 50 | $1,356 |
| Boehringer Ingelheim | 21 | $764 |
| Bayer | 10 | $466 |
| Amgen | 6 | $408 |
| Merck | 6 | $399 |
| Bayer Puerto Rico Inc. | 19 | $396 |
| Abbott | 15 | $362 |
| Dexcom, Inc. | 9 | $347 |
| Eli Lilly Export S.A. Puerto Rico Branch | 9 | $210 |
| Valeritas, Inc. | 1 | $187 |
| Lilly USA, LLC | 1 | $120 |
| Medtronic | 2 | $109 |
| PBG Puerto Rico LLC | 4 | $81 |
| Radius Health, Inc. | 1 | $50 |
| Sanofi | 1 | $43 |
| Novartis | 1 | $20 |
| Pfizer Pharmaceuticals LLC | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INVOKANA$12,394
- SOLIQUA 100/33$4,813
- Synthroid$3,933
- XARELTO$750
- TOUJEO$657
- FARXIGA$375
- Kerendia$347
- Ozempic$345
- JARDIANCE$237
- V-GO$187
- TZIELD$143
- LANTUS$126
- Prolia$125
- EVENITY$125
- LOKELMA$119
- DEXCOM G6 TRANSMITTER$118
- SYNJARDY$112
- TRIJARDY XR$112
- FreeStyle Libre Pro$105
- DEXCOM CGM$102
How this compares
$29,988 in reported general payments places this provider in the 90th percentile of 143 endocrinology, diabetes & metabolism providers in Puerto Rico.
See all endocrinology, diabetes & metabolism providers in Puerto Rico →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 832 | $835,652 |
| OzempicSemaglutide | 534 | $546,841 |
| JardianceEmpagliflozin | 473 | $403,388 |
| FarxigaDapagliflozin Propanediol | 259 | $182,378 |
| TradjentaLinagliptin | 220 | $152,169 |
| SynthroidLevothyroxine Sodium | 1,222 | $132,810 |
| RybelsusSemaglutide | 124 | $124,847 |
| JanuviaSitagliptin Phosphate | 94 | $98,477 |
| MounjaroTirzepatide | 76 | $79,814 |
| LantusInsulin Glargine,hum.Rec.Anlog | 564 | $48,516 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 58 | $47,466 |
| Trijardy XrEmpaglifloz/Linaglip/Metformin | 25 | $25,457 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 32 | $23,616 |
| GlyxambiEmpagliflozin/Linagliptin | 26 | $23,218 |
| JanumetSitagliptin Phos/Metformin Hcl | 28 | $22,368 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro, Humalog, Humulin 70-30, Humalog Mix 75-25 | $120 | $949,9731,280 claims |
| Novo NordiskOzempic, Rybelsus | $1,356 | $671,688658 claims |
| Boehringer IngelheimJardiance, Tradjenta, Trijardy Xr, Synjardy Xr, Glyxambi | $764 | $647,014801 claims |
| AstraZenecaFarxiga | $1,385 | $182,378259 claims |
| MerckJanuvia, Janumet Xr, Janumet | $399 | $168,311180 claims |
| AbbVieSynthroid, Creon | $4,016 | $140,9751,233 claims |
| Sanofi-aventis U.S. LLCLantus | $5,711 | $48,516564 claims |
| AmgenProlia | $408 | $21,51512 claims |
| Johnson & JohnsonInvokana | $13,537 | $11,88414 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 143 endocrinology, diabetes & metabolism providers in Puerto Rico.
Other endocrinology, diabetes & metabolism in San Juan
- Manuel Alegre-HernandezSan Juan$156K
- Monica Ortiz-RiveraSan Juan$148K
- Alex Gonzalez BossoloSan Juan$110K
- Michelle Mangual GarciaSan Juan$87K
- Meliza Martinez RodriguezSan Juan$80K
- Zahira Lugo LopezSan Juan$29K
- Oscar Ruiz BermudezSan Juan$27K
- Margarita Ramirez-VickSan Juan$15K
- Yanira Marrero McFalineSan Juan$14K
- Alfredo Sanchez CruzSan Juan$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.